A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs CX 5461 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 29 May 2015 Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 30 Sep 2013 Status changed from planning to recruiting, according to Australian New Zealand Clinical Trials Registry record.
- 30 Sep 2013 New source identified and integrated: Australian New Zealand Clinical Trials Registry record.